Panacea Acquisition Corp is a Special Purpose Acquisition Company (SPAC) — a blank check company with no operating business. Panacea raised $230M in its IPO in July 2024 and is focused on finding a merger target in the life sciences and healthcare sector, particularly biotechnology. The management team, led by Chairman Ryan Gilbert, CEO Chris Ehrlich, and CFO Jurgen van de Vyver, uses industry networks and relationships with venture capital firms to source and evaluate targets. Panacea had a signed deal with Minovia, a life sciences company, but that deal was mutually terminated in January 2026, and Panacea is now searching for a new target. Panacea has a hard deadline of July 15, 2026 to close a deal, after which it must liquidate and return capital to investors. The $230M raised in the IPO sits in a Trust Account earning interest, with approximately $245M in trust as of December 31, 2025. Public shareholders can redeem their shares for roughly their pro-rata share of the trust if a deal is announced, or hold on and participate in the combined company. The sponsor's economics hinge entirely on closing a deal — management holds "Founder Shares" acquired at nominal cost that are worth significant money if a deal closes, but expire worthless if no deal is completed.